Stock Quote
Merck & Co., Inc. (MRK) (NYSE Arca)
$36.42
23 Nov 2009
-0.11%
$36.42
--
22,751,440
$36.96
$36.19
$36.67
$20.05
0.95
22,135,774
MRK
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Clark, Richard | Chairman of the Board, President, Chief Executive Officer | 19,906,400 |
| Kellogg, Peter | Chief Financial Officer, Executive Vice President | 3,819,080 |
| Schechter, Adam | President - Global Pharmaceuticals | -- |
Profile
Merck & Co., Inc. (Merck) is a global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of products to improve human and animal health. The Company’s operations are principally managed on a products basis and consist of two business segments. The... Full Description
Company Address
Merck & Co., Inc.
One Merck Drive
P.O. Box 100
Whitehouse Station NJ 08889
P: +1908.4231000
F: +1908.7351253
One Merck Drive
P.O. Box 100
Whitehouse Station NJ 08889
P: +1908.4231000
F: +1908.7351253
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Johnson & Johnson | $62.69 | +0.38 |
| Pfizer Inc. | $18.53 | +0.17 |
| GlaxoSmithKline plc | £1,264.50 | -13.00 |
| MRK | Industry | |
|---|---|---|
| P/E(TTM) | 9.58 | 6.90 |
| P/S(TTM) | 4.76 | 1.54 |
| ROI(TTM) | 23.29 | 6.18 |
| ROE(TTM) | 37.81 | 9.32 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | 0.84 |
| EPS Est. (Current Year) | 3.27 |
| Total Revenue | $6,049.70M |
| Net Income | $3,455.30M |
| EPS | $1.61 |
